- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
RANI
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Rani Therapeutics Holdings Inc · Healthcare · Biotechnology
Latest close
0.77 USD
-9.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -23.7% below the Trend Line and sits at 9.7% of its 52-week range. The latest completed week returned -9.0%, after a 0.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.
Setup score
23
out of 100
Latest Close
0.77 USD
31 Jul 2026
1W Return
-9.0%
latest completed week
4W Return
0.4%
short-term follow-through
12W Return
-19.8%
quarterly tape
Trend Breadth
38.5%
20 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-9.0%
Latest completed week; four-week move 0.4%.
Indicator stack
21/51
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.22%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
52/100 conviction; expected move 22.4%.
News sentiment
53/100
59 relevant articles in the latest sentiment read.
Event risk
4d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -23.7% below the Trend Line and sits at 9.7% of its 52-week range. The latest completed week returned -9.0%, after a 0.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0812-week average 0.09
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.4% over four weeks, -19.8% over 12 weeks, and 46.5% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year20
Trend breadth38.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.22Latest activity-pressure read.
Pressure change64.6%Four-week change in activity pressure.
Leadership-34.06Latest relative-leadership reading.
RS change5.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength17/100Blend of value, momentum, and quality. Underlying universe rank 84; rank 1 is best.
Value20/100Relative valuation strength. Underlying universe rank 81; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum86/100Medium-term price momentum. Underlying universe rank 15; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 30.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -17.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 80.3% Gross profit retained from each unit of revenue.
- Operating margin
- -1078.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -536.8% Free cash flow generated from revenue.
- Return on invested capital
- -113.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 164.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -55.0% Net share repurchases relative to market value.
- Shareholder yield
- -55.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
RANI shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 22.4%, and Sharemaestro trend signal inactive.
Conviction52/100
Expected move22.4%
Put/call volume0.00
Insider activity12 / 0
12 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment53/100
Weighted news tone is neutral across 59 relevant articles.
13 positive · 41 neutral · 5 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move22.4%Nearest-chain priced movement where available.
52-week drawdown-80.0%Distance below the 52-week high.
13-week volatility9.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher14 of 2612 weeks finished lower.
Best week+29.2%Week of 17 Apr.
Worst week-28.3%Week of 27 Mar.
Latest week-9.0%Week of 31 Jul.
Shape of recent returns
Strong gains6
Modest gains8
Flat weeks0
Modest losses2
Sharp losses10
Recent vol9.8%13-week weekly-return volatility.
Base vol37.0%52-week weekly-return volatility.
Up/down split23/28Count of positive and negative weeks in the 52-week window.
Average skew18.5% / -8.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape22/100
Trend, activity pressure, participation, and risk combine to a 22/100 tape read.
Indicator analysis10/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.08; No reversal markers Next-Week ExpectancyNegative 40.22%Next-week expectancy is negative with a 40.22% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors30/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 97; Small Cap Core rank 87 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100RANI shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 22.4%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 22.4% Sentiment53/100Weighted news tone is neutral across 59 relevant articles.
Enterprise value to revenue forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI Insiders12 / 012 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 0.77 USD | -9.0% | 1.01 USD | 2.07 USD | -0.22 | -34.06 | 2.6M | Off |
| 24 Jul 2026 | 0.85 USD | 22.0% | 1.03 USD | 2.09 USD | -0.17 | -26.98 | 10.2M | Off |
| 17 Jul 2026 | 0.70 USD | 1.5% | 1.05 USD | 2.11 USD | -0.42 | -40.92 | 4.5M | Off |
| 10 Jul 2026 | 0.69 USD | -10.9% | 1.08 USD | 2.14 USD | -0.50 | -44.03 | 4.6M | Off |
| 3 Jul 2026 | 0.77 USD | 4.8% | 1.10 USD | 2.16 USD | -0.63 | -36.20 | 1.7M | Off |
| 26 Jun 2026 | 0.74 USD | -5.9% | 1.13 USD | 2.18 USD | -0.70 | -38.52 | 3.1M | Off |
| 19 Jun 2026 | 0.78 USD | 2.9% | 1.16 USD | 2.20 USD | -0.65 | -37.56 | 2.4M | Off |
| 12 Jun 2026 | 0.76 USD | -8.4% | 1.19 USD | 2.23 USD | -0.46 | -37.64 | 3.8M | Off |
| 5 Jun 2026 | 0.83 USD | -12.8% | 1.22 USD | 2.25 USD | -0.25 | -30.34 | 5.8M | Off |
| 29 May 2026 | 0.95 USD | -11.1% | 1.26 USD | 2.28 USD | -0.29 | -23.65 | 4.9M | Off |
| 22 May 2026 | 1.07 USD | -0.9% | 1.30 USD | 2.30 USD | -0.39 | -11.38 | 6.9M | Off |
| 15 May 2026 | 1.08 USD | 11.9% | 1.33 USD | 2.32 USD | -0.60 | -9.18 | 6.9M | Off |
| 8 May 2026 | 0.97 USD | 2.7% | 1.35 USD | 2.34 USD | -0.79 | -18.80 | 3.0M | Off |
| 1 May 2026 | 0.94 USD | 0.1% | 1.33 USD | 2.36 USD | -0.93 | -16.73 | 2.4M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.